J Clin Oncol. 1991 Sep;9(9):1668-74.

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

[No authors listed]

Abstract

Four randomized clinical trials comparing cyclophosphamide plus cisplatin (CP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP) individually failed to show a significant survival difference in the treatment of ovarian carcinoma. However, by pooling 1,194 patients from these trials in a meta-analysis, there is a statistically significant survival benefit for CAP (P = .02); in addition, there is a significant advantage for CAP in frequency of negative second-look laparotomy (CAP, 30%; CP, 23%; P = .01). Because the dose intensity of CAP was greater than CP in three of the trials, it remains unresolved to what extent the benefit of CAP is from greater dose intensity and to what extent it is from the doxorubicin itself. Either interpretation suggests directions for improving the chemotherapy of ovarian carcinoma.

PMID:: 1831495; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. [Obstet Gynecol. 1992]
Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Fanning J, Bennett TZ, Hilgers RD. Obstet Gynecol. 1992 Dec; 80(6):954-60.
Review Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. [Gynecol Oncol. 1994]
Review Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T, Vance R, Puneky L, Khansur T. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S97-107.
Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. [Eur J Gynaecol Oncol. 1997]
Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide.
West RJ, Zweig SF. Eur J Gynaecol Oncol. 1997; 18(5):343-8.
The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). [Am J Clin Oncol. 1990]
The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD, Jones HW 3rd, Burnett LS, Johnson DH, Greco FA. Am J Clin Oncol. 1990 Oct; 13(5):410-5.
Review A systematic overview of chemotherapy effects in ovarian cancer. [Acta Oncol. 2001]
Review A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care. Acta Oncol. 2001; 40(2-3):340-60.

See reviews... See all...

Cited by 6 PubMed Central articles

Scope of nanotechnology in ovarian cancer therapeutics. [J Ovarian Res. 2010]
Scope of nanotechnology in ovarian cancer therapeutics.
Yallapu MM, Jaggi M, Chauhan SC. J Ovarian Res. 2010 Aug 6; 3:19. Epub 2010 Aug 6.
Review Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. [Semin Oncol. 2008]
Review Progress in gynecologic cancer research: the Gynecologic Oncology Group experience.
Omura GA, Gynecologic Oncology Group. Semin Oncol. 2008 Oct; 35(5):507-21.
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. [Br J Cancer. 2008]
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
Fruscio R, Colombo N, Lissoni AA, Garbi A, Fossati R, Ieda' N, Torri V, Mangioni C. Br J Cancer. 2008 Feb 26; 98(4):720-7. Epub 2008 Feb 5.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cispla...
Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
J Clin Oncol. 1991 Sep ;9(9):1668-74.

PubMed
Hematopoiesis: an evolving paradigm for stem cell biology.
Hematopoiesis: an evolving paradigm for stem cell biology.
Cell. 2008 Feb 22 ;132(4):631-44.

PubMed
Folate-binding protein is a marker for ovarian cancer.
Folate-binding protein is a marker for ovarian cancer.
Cancer Res. 1991 Oct 1 ;51(19):5329-38.

PubMed
Biomarker discovery in epithelial ovarian cancer by genomic approaches.
Biomarker discovery in epithelial ovarian cancer by genomic approaches.
Adv Cancer Res. 2007 ;96:1-22.

PubMed
Molecular cloning and expression of human tumor-associated polymorphic epithelia...
Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.
J Biol Chem. 1990 Sep 5 ;265(25):15286-93.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

Abstract

Publication Types, MeSH Terms, Substances, Supplementary Concepts

Publication Types

MeSH Terms

Substances

Supplementary Concepts

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Libraries

Supplemental Content

Save items

Related citations in PubMed

Cited by 6 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information